Connect with us

Technology

High Throughput Screening (HTS) Market size is set to grow by USD 19.9 billion from 2024-2028, Rise in R and D investments to boost the market growth, Technavio

Published

on

NEW YORK, July 22, 2024 /PRNewswire/ — The global high throughput screening (HTS) market size is estimated to grow by USD 19.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 12.12%  during the forecast period.  Rise in R and D investments is driving market growth, with a trend towards increasing focus on promotional activities. However, shortage of trained healthcare professionals  poses a challenge. Key market players include Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc..

Get a detailed analysis on regions, market segments, customer landscape, and companies – Click for the snapshot of this report

Forecast period

2024-2028

Base Year

2023

Historic Data

2018 – 2022

Segment Covered

Application (Target identification and validation, Primary and secondary screening, Toxicology assessment, and Stem cell research), End-user (Pharmaceutical and biotechnology companies, Academic and research institutes, and CROs), and Geography (North America, Europe, Asia, and Rest of World (ROW))

Region Covered

North America, Europe, Asia, and Rest of World (ROW)

Key companies profiled

Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc.

Key Market Trends Fueling Growth

The High Throughput Screening (HTS) market faces unique challenges due to the specialized nature of its products and niche end-users. Brand and product visibility play a limited role in sales. Instead, vendors focus on enhancing their distribution networks and ensuring product availability. HTS advertising and marketing are restricted, and awareness is lacking. Thermo Fisher Scientific and Bio-Rad Laboratories use websites, documents, brochures, and interactive videos on YouTube to educate end-users. Workshops are also being conducted to increase awareness. Advanced product development is leading market participants to recognize the importance of promotional activities and awareness programs. These factors are expected to boost the global HTS market during the forecast period. 

High-throughput screening (HTS) is a key trend in the biotech industry, enabling researchers to test large compound libraries for potential drug candidates. Pharmaceutical corporations, biotech startups, academic institutions, and research organizations are leveraging HTS to tackle complex illnesses like cancer and neurological disorders. HTS involves using specialized equipment such as robotic arms, microplate readers, and high-resolution imaging systems for automating target identification and data analysis. Data analytics plays a crucial role in HTS, with machine learning and data management systems used for data organization, retrieval, integration, and storage. Carrier screening market and stem cell research also benefit from HTS. Drug repurposing initiatives, like Adcetris from Seagen, are gaining traction, and collaborative networks among HTS service providers facilitate open innovation models. The biopharmaceutical industry’s focus on precision medicine drives the demand for HTS, with companies investing in computing foundations and chemical databases to support genomic data analysis. Despite advancements, challenges such as false-positive findings and maintenance of specialized equipment persist. The global healthcare sector continues to embrace HTS, fueling growth in this market. Companies like Relay Therapeutics and Biotechnology startups are leading the charge in HTS-driven drug discovery. Toxicology and open innovation models further expand HTS applications. 

Discover 360° analysis of this market. For complete information, schedule your consultation- Book Here!

Market Challenges

The High Throughput Screening (HTS) market faces challenges due to the shortage of skilled professionals in pharmaceutical and biotechnology facilities and laboratories. HTS requires specialized expertise to operate the sensitive equipment and conduct tests effectively. In developing countries, the healthcare system lacks the necessary resources and trained personnel, which hinders the adoption of HTS technology. The absence of skilled technicians can lead to non-compliance, product failures, and significant financial losses for companies. Additionally, the poor healthcare infrastructure and low awareness about advanced technologies in these regions further impede the growth of the HTS market. Government investment in improving healthcare facilities and promoting awareness about HTS technology could help address these challenges and drive market expansion.The High-Throughput Screening (HTS) market is a significant segment of the biotechnology industry, serving the needs of pharma companies, research organizations, and biopharmaceutical industry players. The market faces challenges in areas like carrier screening, target identification, and drug repurposing initiatives. Machine learning and open innovation models are being adopted to overcome these challenges. Relay Therapeutics, a biotech startup, is leveraging HTS for drug discovery using cell-based assays and label-free technology. HTS involves using instruments like robotic arms and microplate readers, along with software and services for data management, storage, organization, retrieval, and integration. Consumables, chemical databases, genomic data, and detection techniques are essential components. HTS is used in stem cell research, toxicology, and precision medicine, and collaborative networks help share knowledge and resources. HTS service providers offer a range of products and services, including instruments, software, and consumables, to support drug development and clinical trials. Technology advancements include lab-on-a-chip and biochemical screening. The global healthcare sector stands to benefit significantly from these innovations.

For more insights on driver and challenges – Download a Sample Report

Segment Overview 

This high throughput screening (hts) market report extensively covers market segmentation by

Application 1.1 Target identification and validation1.2 Primary and secondary screening1.3 Toxicology assessment1.4 Stem cell researchEnd-user 2.1 Pharmaceutical and biotechnology companies2.2 Academic and research institutes2.3 CROsGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Target identification and validation-  The global High Throughput Screening (HTS) market is driven by the increasing burden of chronic diseases, such as cardiovascular diseases, cancer, and respiratory diseases, which necessitates early and comprehensive target identification and validation. Pharmaceutical companies are continuously outsourcing target identification and validation services to meet the rising demand for accurate analytical details on drugs and process development by regulatory agencies. The segment’s growth is further fueled by the increasing pipeline for biological candidates and advancements in target identification and validation using advanced bioinformatics tools, automated experimental designs, and AI and ML algorithms. These factors are expected to foster the growth of the target identification and validation segment in the global HTS market during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2018 – 2022)  – Download a Sample Report

Learn and explore more about Technavio’s in-depth research reports

The global Toxicology Testing Market is experiencing significant growth due to rising awareness of drug safety and stringent regulatory policies. Meanwhile, the global Genome Editing Market is expanding rapidly, driven by advancements in CRISPR technology and increased investment in genetic research. Additionally, the global Modular Laboratory Automation Market is thriving as laboratories seek efficient, scalable solutions to enhance productivity and accuracy. Together, these markets represent pivotal areas in the biotechnology and healthcare sectors, fostering innovation and improving outcomes across various scientific and medical disciplines.

Research Analysis

High-throughput screening (HTS) is a critical technology in the field of drug discovery and research, enabling the rapid and efficient identification of potential therapeutic compounds. HTS utilizes large compound libraries, often numbering in the millions, to screen for compounds that exhibit desirable biological activity. Academic institutions and biotech startups collaborate with pharmaceutical corporations to leverage their expertise and resources in this area. Complex illnesses such as cancer and neurological disorders are major targets for HTS, with a focus on developing new treatments and repurposing existing drugs. Robotic arms, microplate readers, high-resolution imaging systems, and data management systems are essential tools in the HTS process. Data analytics plays a crucial role in organizing, retrieving, integrating, and storing data from HTS experiments. Chemical databases, research organizations, toxicology, open innovation models, and the global healthcare sector are also integral components of the HTS market. Adcetris from Seagen is an example of a successful drug discovered through HTS. Drug repurposing, stem cell research, and data retrieval are other areas of focus in the HTS market.

Market Research Overview

High Throughput Screening (HTS) is a critical technology in the life sciences sector, enabling the rapid and efficient identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. HTS utilizes compound libraries, automation, and specialized equipment like robotic arms, microplate readers, and high-resolution imaging systems to screen large numbers of compounds against specific targets. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to organize, retrieve, integrate, and analyze vast amounts of genomic data and chemical information. Collaborative networks and HTS service providers facilitate open innovation models and knowledge sharing among academic institutions, biotech startups, pharmaceutical corporations, and research organizations. Drug repurposing initiatives, such as those by Biotechnology startups like Relay Therapeutics, offer new opportunities for discovering existing drugs with potential applications for new diseases. The biopharmaceutical industry, global healthcare sector, and precision medicine are major markets for HTS, with a focus on detection techniques, clinical trials, and the development of products and services including consumables, software, and services. Technology advancements like cell-based assays, lab-on-a-chip, and label-free technology continue to drive innovation in HTS. Toxicology and stem cell research are also significant applications of HTS. Overall, HTS is a vital component of drug discovery and development, contributing to the advancement of new treatments for chronic diseases and other health conditions.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ApplicationTarget Identification And ValidationPrimary And Secondary ScreeningToxicology AssessmentStem Cell ResearchEnd-userPharmaceutical And Biotechnology CompaniesAcademic And Research InstitutesCROsGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/high-throughput-screening-hts-market-size-is-set-to-grow-by-usd-19-9-billion-from-2024-2028–rise-in-r-and-d-investments-to-boost-the-market-growth-technavio-302202266.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Kratos Capital Announces Acquisition of Weldon Services by Upchurch Services, LLC

Published

on

By

This acquisition strengthens Upchurch’s market position while unlocking new growth potential for Weldon Services.

DALLAS, Sept. 27, 2024 /PRNewswire-PRWeb/ — Kratos Capital, a leading mergers and acquisitions advisor for privately held, middle-market businesses, is pleased to announce the successful acquisition of Weldon Services by Upchurch Services, LLC, a portfolio company of Broadwing Capital. This strategic acquisition allows Upchurch Services, LLC to enter the highly sought-after Dallas/Fort Worth Metropolitan Statistical Area (MSA), expanding their market presence and service capabilities. The deal was closed on September 12, 2024.

Weldon Services, known for providing exceptional mechanical, electrical, and plumbing (MEP) services across Dallas and Ft. Worth, brings decades of expertise and a strong client base. By joining forces with Upchurch Services, LLC, a prominent provider of specialty contracting services backed by Broadwing Capital, both companies are poised for significant growth.

This acquisition provides Upchurch with an important foothold in the Dallas/Fort Worth MSA, one of the fastest-growing metropolitan areas in the country. The region offers significant opportunities for expansion in commercial and residential markets, and the addition of Weldon Services’ capabilities further strengthens Upchurch’s service offerings in mechanical and electrical contracting.

Kratos Capital, a trusted name in managing complex M&A transactions, facilitated the deal, ensuring a seamless integration of Weldon Services into the Upchurch portfolio. The partnership between Weldon Services and Upchurch Services, LLC is expected to create new opportunities for both companies while enhancing their ability to deliver top-tier services to clients in the region.

Additional information regarding Kratos Capital, its M&A services, and previous M&A dealings can be found on the company website.

Kratos Capital is a distinguished M&A firm with over a century of combined experience in the industry, dedicated to exceeding client expectations through expertly crafted exit strategies that maximize shareholder value. Serving clients across the United States, Canada, and South America, they specialize in enhancing the sale and divestiture process using proprietary technology and a principal mentality to ensure successful and satisfying transitions.

Media Contact

Josh Bammel, Kratos Capital, 1 (214)684-9101, josh@kratoscap.comhttps://www.kratoscapital.com/

View original content to download multimedia:https://www.prweb.com/releases/kratos-capital-announces-acquisition-of-weldon-services-by-upchurch-services-llc-302259591.html

SOURCE Kratos Capital

Continue Reading

Technology

AT&T Declares Dividends on Common and Preferred Shares

Published

on

By

DALLAS, Sept. 27, 2024 /CNW/ — The board of directors today declared a quarterly dividend of $0.2775 per share on the company’s common shares, payable November 1, 2024.

Key Takeaways:

The board of directors declared a quarterly dividend of $0.2775 per share on the company’s common shares.Dividends on common stock as well as Series A and Series C preferred stock are payable on November 1, 2024.

The board of directors of AT&T (NYSE: T) today declared a quarterly dividend of $0.2775 per share on the company’s common shares.

The board of directors also declared quarterly dividends on the company’s 5.000% Perpetual Preferred Stock, Series A and the company’s 4.750% Perpetual Preferred Stock, Series C. The Series A dividend is $312.50 per preferred share, or $0.3125 per depositary share. The Series C dividend is $296.875 per preferred share, or $0.296875 per depositary share.

Dividends on the common stock and Series A and Series C preferred stock are payable on November 1, 2024, to stockholders of record of the respective shares at the close of business on October 10, 2024.

About AT&T

We help more than 100 million U.S. families, friends and neighbors, plus nearly 2.5 million businesses, connect to greater possibility. From the first phone call 140+ years ago to our 5G wireless and multi-gig internet offerings today, we @ATT innovate to improve lives. For more information about AT&T Inc. (NYSE:T), please visit us at about.att.com. Investors can learn more at investors.att.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/att-declares-dividends-on-common-and-preferred-shares-302261477.html

SOURCE AT&T

Continue Reading

Technology

Renal Support Network to Host 31st Annual Kidney Disease Education and Lifestyle Meeting Virtually

Published

on

By

Hope Week 2024 Offers Five Days of Inspiration, Education, and Support for People Living with Kidney Disease, Their Families, and Healthcare Professionals

GLENDALE, Calif., Sept. 27, 2024 /PRNewswire-PRWeb/ — Renal Support Network (RSN) will host its 31st Annual Kidney Disease Education and Lifestyle Meeting from October 9th-13th, 2024. For over three decades, RSN has hosted this highly regarded event, providing education, resources, and support for people living with kidney disease, their families, and healthcare professionals. This event, aptly named Hope Week, will continue this tradition with a focus on fostering hope and empowerment for those affected by kidney disease.

RSN Founder/ President Lori Hartwell reflects, “Fear arises from a lack of understanding, and loneliness can be eased by connecting with a community that truly understands what you’re going through. Hope Week addresses these challenges. Knowledge and confidence in navigating care is within reach.”

Each day of the event will center on a different stage or aspect of chronic kidney disease (CKD), covering topics such as diagnosis, dialysis, kidney transplant, and daily lifestyle challenges. Esteemed healthcare professionals, along with those from within the kidney community who have learned to thrive in spite of having kidney disease, will share their expertise, advice, and personal stories, offering valuable insight into living and thriving with CKD.

RSN remains committed to equitable access to information and resources, ensuring that no individual faces barriers to participation. By utilizing a virtual platform, the meeting allows those who may face physical, geographic, or financial constraints to engage fully in the event.

Hope Week provides not only education but also inspiration and a chance to connect with a supportive community of people who have been there. It’s a unique opportunity to hear firsthand from those who have walked the path and to learn about the latest advancements in kidney care.

RSN Founder and President Lori Hartwell reflects, “Throughout my journey—marked by more than 50 surgeries, 13 years on dialysis, and four kidney transplants—I’ve faced some of life’s toughest lessons. These were not the lessons you learn in school, but ones born from personal experience. I know many of my peers share the same fears and feelings of isolation that I’ve experienced. Fear often arises from a lack of understanding, and loneliness can be eased by connecting with a community that truly understands what you’re going through. That’s exactly what Hope Week provides: five days of inspiration and education designed to address these challenges. One of the cornerstones of RSN is the motto, ‘an illness is too demanding when you don’t have hope’, and Hope Week is here to remind everyone that connection, knowledge and confidence in navigating care is within reach.”

Key Event Highlights:

There are no fees to attend.

Free Gift for Attending: All attendees receive a complimentary gift from RSN.

The event starts later in the afternoon on the weekdays so that people who work can attend.

Daily Focused Sessions: Each day will highlight a different stage or aspect of CKD, including topics such as diagnosis, dialysis, kidney transplants, and the management of daily lifestyle issues.

Expert Speakers and Panelists: Renowned healthcare professionals and experts from the kidney community will offer advice and discuss the latest developments in kidney care.

Patient and Caregiver Stories: Attendees will have the opportunity to hear inspiring personal stories from patients and caregivers who have firsthand experience managing CKD.

Interactive Q&A Sessions: Participants will be able to engage directly with speakers and panelists, asking questions and gaining insight into various aspects of kidney disease management.

Access for All: The virtual platform ensures that individuals from across the globe can participate, regardless of their location or circumstances.

Networking and Support: Hope Week will also feature opportunities to connect with others who are experiencing similar challenges, creating a supportive and uplifting environment.

Youth and Family Day: Parents share their tips for coping with challenges of a busy family life and young adults share their stories about transitioning to adulthood, finding independence, a career, dating and school.

Lifestyle Expo: Explore virtual booths featuring kidney-friendly products, services, and resources.

To see the full agenda and to register go to RSNHope.org/HopeWeek.

RSN would like to thank our 2024 Hope Week sponsors: Akebia, Amgen, Alexion, Ardelyx, AstraZeneca and U.S. Renal Care.

The Renal Support Network is a Registered 501(c)(3) Non-profit and serve people throughout the United States.

Lori Hartwell founded Renal Support Network in 1993 to empower people who have kidney disease to become knowledgeable about their illness, proactive in their care, hopeful about their future and make friendships that last a lifetime. Lori suffered kidney failure at the age of two, survived 50+ surgeries and 13 years of dialysis, and is now living with her fourth kidney transplant.

RSN’s hopeful and life-enriching, non-medical programs help people who have kidney disease and their families, whether they are in the early stages of the disease, are on dialysis, or have received a transplant. www.RSNhope.org.

Media Contact

Suzette Maffi, Renal Support Network, 1 (818) 543-0896, Info@RSNhope.org, https://www.rsnhope.org/

View original content to download multimedia:https://www.prweb.com/releases/renal-support-network-to-host-31st-annual-kidney-disease-education-and-lifestyle-meeting-virtually-302259594.html

SOURCE Renal Support Network

Continue Reading

Trending